Increasing demand for oncology drugs
HPAPIs are extremely effective pharmacologically active ingredients. They are highly specific in their action and offer significant efficiency even at low daily therapeutic doses. HPAPIs have the ability to target precise disease cells and are, hence, used in formulations for highly potent drugs.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. According to the WHO, in 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) worldwide. The American cancer Society estimated that over 15.5 million American citizens were suffering from cancer as of January 2016, with over 1,688,780 new cancer cases expected to be diagnosed in 2017.
This growth in the number of cancer cases has a tremendous impact on the sales of cancer drugs across the globe. According to an article published in Nature Reviews, the pharmaceutical industrys 20 top-selling cancer drugs generate annual sales of over USD 50 billion worldwide, with Roche's Rituxan, Avastin, and Herceptin in the leading position generating USD 21 billion in sales.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36582475
Global Revenue Growth Expectations:
The global HPAPI market is expected to reach USD 26.84 Billion by 2023 from USD 16.49 Billion in 2017, at a CAGR 8.7%. The base year considered for the study is 2017 and the forecast period is from 2018 to 2023.
Requirement of large investments
The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure.
Although the HPAPIs market is an emerging and growing market, pharmaceutical manufacturers face significant challenges in upgrading their existing facilities that are capable of handling only low- or medium-potency APIs. Specialized containment to ensure protection of the employees and their environment from exposure accounts for a major cost. Contract manufacturers are required to heavily invest in building new facilities that are designed specifically for HPAPI manufacturing apart from the usual GMP production facilities; investments may sometimes amount to millions of dollars.
Manufacturers may also be required to invest in specialized facilities for HPAPI-antibody conjugations that incorporate both potent-compound handling and biologics processing capabilities. For instance, in October 2015, ADC Biotechnology (UK), invested USD 10 million to build a manufacturing facility for advanced anti-cancer drugs. These requirements of large investments is likely to restrain the growth of this market.
Opportunity in emerging markets
Emerging economies such as India, China, and the Middle East present high growth opportunities for players in the HPAPIs market. In most of these geographies, the market is expected to show a high growth rate in the coming years owing to their huge population, increasing prosperity, and improving longevity (albeit at differing rates).
Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries. According to the WHO, in 2014, nearly 66% of all cancer-related deaths occurred in developing countries. Additionally, according to GLOBOCAN 2012, a total of 6.8 million new cancer cases were reported in 2012 in Asia; this is expected to reach 8.4 million cases by 2020, indicating an increase of ~24%.
Furthermore, developing regions have lenient and flexible regulations, which make these markets highly lucrative for providers who are unable to meet the stringent standards set by the federal government in the US. Moreover, developing countries like India and China offer extremely low manufacturing and labor costs and highly skilled labor; this encourages players in developed regions to invest in this market.
Constant evolution of industry standards and technologies
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations. Companies that are willing to enter this marker are required to adopt these newer technologies, which generally translates to huge investments. For example, SAFC (US) had to upgrade its HPAPI manufacturing facility in the US in 2016 to include more robust analytical technologies with improved sensitivity and detection levels that allow for the determination of potential API carryover at part-per-billion levels. Such a rapidly evolving environment poses a challenge to the players in this market.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=36582475
The objectives of this study are as follows:
# To define, describe, and forecast the global HPAPI market on the basis of type, type of manufacturer, type of synthesis, therapeutic application, and region.
# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).
# To strategically analyze micromarkets with respect to the individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of the market segments of North America, Europe, Asia, and the Rest of the World (RoW).
# To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies.
# To track and analyze competitive developments such as agreements, partnerships, collaborations, and alliances; mergers and acquisitions; expansions; and R&D activities in the global market.
Speak to Analyst@
https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=36582475
In this report, our team offers a comprehensive analysis of High Potency APIs (HPAPI) market, SWOT analysis of the most prominent players in this landscape.
Along with an industrial chain, market statistics in terms of revenue, sales, price, capacity, regional market analysis, segment-wise data, and market forecast information are offered in the full study, etc.
Download Free Sample Report @ https://www.radiantinsights.com/research/global-high-potency-apis-hpapi-market-2020-2026/request-sample This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering• AbbVie• AstraZeneca plc• Bayer• Boehringer Ingelheim• Bristol-Myers Squibb• Eli Lilly and Company• F. Hoffmann-La Roche• GlaxoSmithKline plc• Merck & Co.• Mylan• Novartis International AG• Pfizer• Sanofi• Teva Pharmaceutical Industries Ltd. On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into• Innovative HPAI• Generic HPAI By Application, this report focuses on Sales, Market share and Growth Rate of each application, can be divided into• Oncology• Hormonal• Glaucoma• Others By Regions, this report splits global market into several key regions, with Sales, Revenue, Price and Gross Margin market share of top players in these regions, from 2014 to 2026 (forecast), like• China• USA• Europe• Japan• Korea• India• Southeast Asia• South America Browse Full Research Report with TOC @ https://www.radiantinsights.com/research/global-high-potency-apis-hpapi-market-2020-2026 Table of Contents Global High Potency APIs (HPAPI) Market Professional Survey Report 20191 Report Overview1.1 Definition and Specification1.2 Manufacturers and Region Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.3 Type Overview1.3.1 Innovative HPAI1.3.2 Generic HPAI1.4 Application Overview1.4.1 Oncology1.4.2 Hormonal1.4.3 Glaucoma1.4.4 Others1.5 Industrial Chain1.5.1 High Potency APIs (HPAPI) Industrial Chain1.5.2 Upstream1.5.3 Downstream 2.1 The Overall Market Performance(Volume)2.1.1 Innovative HPAI2.1.2 Generic HPAI2.2 The Overall Market Performance(Value)2.2.1 Innovative HPAI2.2.2 Generic HPAI 3 Global High Potency APIs (HPAPI) Market Assessment by Application3.1 Overall Market Performance (Volume)3.2 Oncology3.3 Hormonal3.4 Glaucoma3.5 Others Continued… Read all Reports of this category @ https://www.radiantinsights.com/catalog/ict About Radiant InsightsRadiant Insights is a platform for companies looking to meet their market research and business intelligence requirements.
It assists and facilitate organizations and individuals procure market research reports, helping them in the decisions making process.
The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
High Potency API Market Synopsis:Active pharmaceutical ingredient, or API, is basically the component within any prescribed drug that releases its effect on the human body.
Every drug that is developed carries two core components, the API and the excipients, which are the chemically inactive parts of the drug.
Targeted therapy is one of the latest methods of dealing with ailments that make use of high potency APIs.Avail FREE Sample at: https://www.marketresearchfuture.com/sample_request/6679Global Market for High Potency APIs – Competitive Dashboard:Some of the key players profiled in the report are –Teva PharmaceuticalsSAFCCarbogen AmicsBristol-Myers SquibbAsymchemLonzaBayer AGBoehringer IngelheimSanofi.Market SegmentationThe latest report published by Market Research Future (MRFR) states that the high potency APIs market is segmented on the basis of therapeutic area, type, and product.By product, the market divides into biotech and synthetic.
It is expected to see that the rising demand for antibody-drug conjugates (ADCs) will lead to the market growth of the biotech segment in the forthcoming years.By type, the market includes generic and novel or innovative.
This can be attributed to the availability of huge funds for research & development purposes by the manufacturers.By therapeutic area, the market comprises hormonal, oncology, glaucoma, and others.
Among all the segments, glaucoma is believed to witness significant growth and demand over the assessment period.LIST OF TABLESTable 1 Global High Potency APIs Market Synopsis, 2018–2023Table 2 Global High Potency APIs Market Estimates And Forecast, 2018–2023, (USD Million)Table 3 Global High Potency APIs Market, By Region, 2018–2023, (USD Million)Table 4 Global High Potency APIs Market, By Product, 2018–2023, (USD Million)Table 5 Global High Potency APIs Market, By Type, 2018–2023, (USD Million)Table 6 Global High Potency APIs Market, By Therapeutic Area, 2018–2023, (USD Million)Table 7 North America Global High Potency APIs Market, By Product, 2018–2023, (USD Million)Table 8 North America Global High Potency APIs Market, By Therapeutic Area, 2018–2023,(USD Million)… To be Continued.Get Full Detailed Copy of This Report at: https://www.marketresearchfuture.com/reports/high-potency-apis-market-6679Regional AnalysisThe geographical high potency APIs market segmentation covers Europe, Asia-Pacific, Americas, and the Middle East & Africa.North America holds the top spot in terms of the market growth of high potency APIs and is expected to witness substantial growth over the forecast period.
